Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib

Hematol Oncol. 2018 Feb;36(1):357-359. doi: 10.1002/hon.2424. Epub 2017 May 5.

Authors

Annalisa Pacilli¹, Tiziana Fanelli^{1

2}, Carmela Mannarelli¹, Giada Rotunno¹, Alessandro Pancrazzi¹, Alessandro Maria Vannucchi¹, Paola Guglielmelli¹

Affiliations

¹ CRIMM-Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical medicine, University of Florence, Florence, Italy.
² GenOMec, University of Siena, Siena, Italy.

PMID: 28474777
DOI: 10.1002/hon.2424

No abstract available

Keywords: JAK2 46/1 haplotype; JAK2V617F architecture; myeloproliferative neoplasms; ruxolitinib.

Publication types

Letter

MeSH terms

Amino Acid Substitution
Cells, Cultured
Female
Follow-Up Studies
Humans
Janus Kinase 2 / genetics*
Janus Kinase 2 / metabolism
Male
Mutation, Missense*
Myeloproliferative Disorders / drug therapy*
Myeloproliferative Disorders / genetics*
Myeloproliferative Disorders / metabolism*
Rituximab / pharmacology*

Substances

Rituximab
JAK2 protein, human
Janus Kinase 2